Interaction of cyclosporin derivatives with the ATPase activity of human P-glycoprotein

British Journal of Pharmacology

Volumn 122, Issue 2, 1997, Pages 241-248

  Watanabe, Toru ^a   Kokubu, Noriko ^a   Charnick, Steven B ^b   Naito, Mikihiko ^c   Tsuruo, Takashi ^c,d   Cohen, Dalia ^b  

^a NOVARTIS PHARMA K K   (Japan)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF TOKYO   (Japan)

^d CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

ATPase; Cyclosporin A; Multidrug resistance; P glycoprotein; PSC 833

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; VALSPODAR; VERAPAMIL; VINBLASTINE;

ARTICLE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; AFFINITY LABELS; AZIDES; CYCLOSPORINE; CYCLOSPORINS; HUMANS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0030882716     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701377     Document Type: Article

References (50)

1. AL-SHAWI, M.K., URBATSCH, I.L., & SENIOR, A.E. (1994). Covalent inhibitors of P-glycoprotein ATPase activity. J. Biol. Chem., 269, 8986-8992.
2. AMBUDKAR, S.V., LELONG, I.H., ZHANG, J., CARDARELLI, C.O., GOTTESMAN, M.M. & PASTAN, I. (1992). Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc. Natl. Acad. Sci. U.S.A., 89, 8472-8476.
3. AMBUDKAR, S.V., RAMACHANDRA, M., CARDARELLI, C.O., PASTAN, I. & GOTTESMAN, M.M. (1996). Modulation of human P-glycoprotein ATPase activity by interaction between over-lapping substrate-binding sites. Proc. Am. Assoc. Cancer Res., 37, 325.
4. ARCHINAL-MATTHEIS, A., RZEPKA, R.W., WATANABE, T., KOKUBU, N., ITOH, Y., COMBATES, N.J., BAIR, K.W. & COHEN, D. (1995). Analysis of the interaction of SDZ PSC 833 ([3′-keto-Bmt1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol. Res., 12, 603-610.
5. BOESCH, D., GAVERIAUX, C., JACHEZ, B., POURTIER-MANZANEDO, A., BOLLINGER, P. & LOOR, F. (1991a). In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 51, 4226-4233.
6. BOESCH, D., MULLER, K., POURTIER-MANZANEDO, A. & LOOR, F. (1991b). Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res., 196, 26-32.
7. BRUGGEMANN, E.P., CURRIER, S.J., GOTTESMAN, M.M. & PASTAN, I. (1992). Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J. Biol. Chem., 267, 21020-21026.
8. BRUGGEMANN, E.P., GERMANN, U.A., GOTTESMAN, M.M. & PASTAN, I. (1989). Two different regions of p-glycoprotein are photoaffinity-labeled by azidopine. J. Biol. Chem., 264, 15483-15488.
9. CARDARELLI, C.O., AKESENTIJEVICK, I., PASTAN, I. & GOTTESMAN, M.M. (1995). Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res., 55, 1086-1091.
10. CHOI, K.H., CHEN, C.J., KRIEGLER, M. & RONINSON, I.B. (1988). An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell, 53, 519-529.
11. DONG, J., NAITO, M., TATSUTA, T., SEIMIYA, H., JOHDO, O. & TSURUO, T. (1995). Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Oncol. Res., 7, 245-252.
12. FORD, J.M. & HAIT, W.N. (1990). Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42, 155-199.
13. GARRIGOS, M., BELEHRADEK, JR., J., MIR, L.M. & ORLOWSKI, S. (1993). Absence of cooperatively for MgATP and verapamil effects on the ATPase activity of P-glycoprotein containing membrane vesicles. Bioehem. Biophys. Res. Commun., 196, 1034-1041.
14. GEORGES, E., ZHANG, J.-T. & LING, V. (1991). Modulation of ATP and drug binding by monoclonal antibodies against P-glycoprotein. J. Cell. Physiol., 148, 479-484.
15. GILL, D.R., HYDE, S.C., HIGGINS, C.F., VALVERDE, M.A., MINTENIG, G.M. & SEPÚLVEDA, F.V. (1992). Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell, 71, 23-32.
16. GOTTESMAN, M.M. & PASTAN, I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427.
17. GREENBERGER, L.M. (1993). Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. J. Biol. Chem., 268, 11417-11425.
18. GREENBERGER, K.M., LISANTI, C.J., SILVA, J.T. & HORWITZ, S.B. (1991). Domain mapping of the Photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1b. J. Biol. Chem., 266, 20744-20751.
19. HAMADA, H. & TSURUO, T. (1986). Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A., 83, 7785-7789.
20. HAMADA, H. & TSURUO, T. (1988a). Purification of the 170-to 180-kilodalton membrane glycoprotein associated with multidrug resistance. J. Biol. Chem., 263, 1454-1458.
21. HAMADA, H. & TSURUO, T. (1988b). Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res., 48, 4926-4932.
22. JACHEZ, B., CIANFRIGLIA, M. & LOOR, F. (1994). Modulation of human P-glycoprotein epitope expression by temperature and/or resistance-modulating agents. Anti-Cancer Drugs, 5, 655-665.
23. KAJIJI, S., DRESLIN, J.A., GRIZZUTI, K. & GROS, P. (1994). Structurally distinct MDR modulators show specific patterns of reversal against P-glycoprotein bearing unique mutations at Serine939/941. Biochemistry, 33, 5041-5048.
24. KAJIJI, S., TALBOT, F., GRIZZUTI, K., VAN DYKE-PHILLIPS, V., AGRESTI, M., SAFA, A.R. & GROS, P. (1993). Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. Biochemistry, 32, 4185-4194.
25. KOKUBU, N., COHEN, D. & WATANABE, T. (1997). Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal antibody against P-glycoprotcin. Biochem. Biophys. Res. Commun., 230, 398-401.
26. HAEMMLI, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
27. LAMPIDIS, T.J., KOLONIAS, D., PODONA, T., ISRAEL, M., SAFA, A.R., LOTHSTEIN, L., SAVARAJ, N., TAPIERO, H. & PRIEBE, W. (1997). Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry, 36, 2679-2685.
28. LOO, T.W. & CLARKE, D.M. (1994). Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry, 33, 14049-14057.
29. LOO, T.W. & CLARKE, D.M. (1996). Inhibition of oxidative cross-linking between engineered cysteine residues at position 332 in predicted transmembrane segments(TM) 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates. J. Biol. Chem., 271, 27482-27487.
30. LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
31. MINTENIG, G.M., VALVERDE, M.A., SEPÚLVEDA, F.V., GILL, D.R., HYDE, S.C., KIRK, J. & HIGGINS, C.F. (1993). Specific inhibitors distinguish the chloride channel and drug transporter functions associated with the human multidrug resistance P-glycoprotein. Receptors Channels, 1, 305-313.
32. NAITO, M., TSUGE, H., KUROKO, C., KOYAMA, T., TOMIDA, A., TATSUTA, T., HEIKE, Y. & TSURUO, T. (1993). Enhancement of cellular accumulation of cyclosporin e by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J. Natl. Cancer Inst., 85, 311-316.
33. NAITO, M., WATANABE, T., TSUGE, H., KOYAMA, T., OH-HARA, T. & TSURUO, T. (1996). Potentiation of the reversal activity of SDZ PSC833 on multi-drugresistance by anti-P-glycoprotein monoclonal antibody MRK-16. Int. J. Cancer, 67, 435-440.
34. RAMACHANDRA, M., AMBUDKAR, S.V., GOTTESMAN, M.M., PASTAN, I. & HRYCYNA, C.A. (1996). Functional characterization of a Glycine 185-to-Valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system. Mol. Biol. Cell, 7, 1485-1498.
35. RAO, U.S. (1995). Mutation of Glycine 185 to Valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. J. Biol. Chem. 270, 6686-6690.
36. RAO, U.S. & SCARBOROUGH, G.A. (1994). Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol. Pharmacol., 45, 773-776.
37. SAEKI, T., UEDA, K., TANIGAWARA, Y., HORI, R. & KOMANO, T. (1993). Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem., 268, 6077-6080.
38. SAFA, A.R., STERN, R.K., CHOI, K., AGRESTI, M., TAMAI, L., MEHTA, N.D. & RONINSON, I.B. (1990). Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185→Val-185 substitution in P-glycoprotein. Proc. Natl. Acad. Sci. U.S.A., 87, 7225-7229.
39. SARKADI, B., MÜLLER, M., HOMOLYA, L., HOLLó, Z., SEPRöDI, J., GERMANN, U.A., GOTTESMAN, M.M., PRICE, E.M. & PASTAN, I. (1994). Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB J., 8, 766-770.
40. SARKADI, B., PRICE, E.M., BOUCHER, R.C., GERMANN, U.A. & SCARBOROUGH, G.A. (1992). Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem., 267, 4854-4858.
41. SHAROM, F.J., DIDIODATO, G., YU, X. & ASHBOURNE, J.D. (1995). Interaction of the P-glycoprotein multidrug transporter with peptide and ionophores. J. Biol. Chem., 270, 10334-10341.
42. SHAROM, F.J., YU, X. & DOIGE, C.A. (1993). Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J. Biol. Chem., 268, 24197-24202.
43. SHIMABUKU, A.M., NISHIMOTO, T., UEDA, K. & KOMANO, T. (1992). P-glycoprotein ATP hydrolysis by the N-terminal nucleotide-binding domain. J. Biol. Chem., 267, 4308-4311.
44. SHIRAI, A., NAITO, M., TATSUTA, T., DONG, J., HANAOKA, K., MIKAMI, K., OH-HARA, T. & TSURUO, T. (1994). Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim. Biophys. Acta, 1222, 400-404.
45. TAMAI, I. & SAFA, A.R. (1990). Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J. Biol. Chem., 265, 16509-16513.
46. TSURUO, T. (1988). Mechanisms of multidrug resistance and implications for therapy. Jpn. J. Cancer Res., 79, 285-296.
47. TSURUO, T., IIDA-SAITO, H., KAWABATA, H., OH-HARA, T., HAMADA, H. & UTAKOJI, T. (1986). Characteristics of resistance to Adriamycin in human myelogenous leukemia K562 resistant to Adriamycin and in isolated clones. Jpn. J. Cancer Res., 77, 682-692.
48. 185→Val substitution in human P-glycoprotein on the reversal activity of PSC 833. Proc. Am. Assoc. Cancer Res., 37, 334.
49. WATANABE, T., NAITO, M., OH-HARA, T., ITOH, Y., COHEN, D. & TSURUO, T. (1996b). Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models. Jpn. J. Cancer Res., 87, 184-193.
50. YAMAOKA, K., TANIGAWARA, Y., NAKAGAWA, T. & UNO, T. (1981). A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-lyn., 4, 879-885.